2096 — Simcere Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$27.27bn
- HK$24.00bn
- CNY7.73bn
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660
Brief: Simcere Pharmaceutical To Repurchase Shares In Open Market Up To RMB1,000 Million
China's Simcere Pharmaceutical H1 revenue rises on neuroscience, autoimmune drugs strength
Brief: Simcere Pharmaceutical Posts HY Net Income Attributable Of RMB 829 MLN
Brief: Simcere Pharmaceutical Expects 1H 2026 Revenue Of RMB4,550 Million-RMB4,610 Million
Brief: Simcere Pharmaceutical Says Sanbexin Included In 2026 National Essential Medicines List
Brief: Simcere Pharmaceutical Receives Clinical Trial Approval For SIM0689 From China's NMPA
Brief: Simcere Pharmaceutical Enters Exclusive Promotion Service Agreement With Primegenx Therapeutics
Brief: Simcere Pharmaceutical Receives NMPA China Clinical Trial Approval For SIM0613
Brief: Simcere Pharmaceutical Says NDA For Rademikibart Accepted By NMPA
Brief: Simcere Pharma Withdraws NDA For Rademikibart, Expects To Resubmit Within April 2026
Brief: Simcere Pharmaceutical Posts FY Profit Attributable Rmb1,344 Million
Brief: Simcere Pharmaceutical Says Unit To Buy Entire Stake In Target Company For RMB30.8 Million
Brief: Simcere Pharmaceutical Says Zhou Yunshu Appointed As CEO
Simcere jumps on pharma licensing deal with Boehringer Ingelheim
Brief: Simcere Pharmaceutical Enters Exclusive Licensing Agreement With Boehringer Ingelheim